biostudies-literatureUnknown25(2)Garcia J<h4>Background and objectives</h4>The use of ultra-sensitive diagnostic tests to detect clinically actionable somatic alterations within the gene encoding the epidermal growth factor receptor (EGFR) within circulating cell-free DNA is an important first step in determining the eligibility of patients with non-small cell lung cancer to receive tyrosine kinase inhibitors.<h4>Methods</h4>We present the clinical validation (accuracy, sensitivity, and specificity) of a highly sensitive OncoBEAM^TM EGFR V2 test, which we compare to a custom next-generation sequencing assay, for the treatment of patients with non-small cell lung cancer with EGFR tyrosine kinase inhibitor therapies. The OncoBEAM^TM digital-polymerase chain reaction method detects 36 different EGFR alterations iMolecular diagnosis & therapy239-250https://www.ebi.ac.uk/biostudies/studies/S-EPMC7956937biostudies-literatureRoutine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAM^TM EGFR V2 and NGS Technologies.PMC7956937Couraud SDuruisseau MPayen LBarthelemy DGeiguer FGauthier AGarcia JMerle PBalandier JJones FSHoltrup FEdelstein DLGrolleau ELescuyer GRodriguez-Lafrasse CfalseRoutine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAM^TM EGFR V2 and NGS Technologies.<h4>Background and objectives</h4>The use of ultra-sensitive diagnostic tests to detect clinically actionable somatic alterations within the gene encoding the epidermal growth factor receptor (EGFR) within circulating cell-free DNA is an important first step in determining the eligibility of patients with non-small cell lung cancer to receive tyrosine kinase inhibitors.<h4>Methods</h4>We present the clinical validation (accuracy, sensitivity, and specificity) of a highly sensitive OncoBEAM^TM EGFR V2 test, which we compare to a custom next-generation sequencing assay, for the treatment of patients with non-small cell lung cancer with EGFR tyrosine kinase inhibitor therapies. The OncoBEAM^TM digital-polymerase chain reaction method detects 36 different EGFR alterations i2021-01-01T00:00:00Z2021 Mar2026-05-07T12:02:03.435Z2022-02-09T08:14:40.384ZS-EPMC79569373366018810.1007/s40291-021-00515-9